XLONasdaqPharmaceutical PreparationsUS GAAP · USD

Xilio Therapeutics, Inc.

Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer. Its pipeline includes masked antibody-based therapies and other engineered biologics designed to activate in the tumor microenvironment, with development conducted through its wholly owned subsidiary, Xilio Development, Inc.

Kysy yhtiöstä
Liikevaihto43,8milj. USD
+589,9 %v/v
Liikevoitto (EBIT)−42,0milj. USD
+30,7 %v/v
EBIT-marginaali−95,9%
+859,0 %-yks.v/v
Nettotulos−35,0milj. USD
+39,8 %v/v
Vapaa kassavirta−5,5milj. USD
+70,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−50050milj. USD2020: EBIT −55 milj. USD20202021: EBIT −75 milj. USD20212022: EBIT −89 milj. USD20222023: EBIT −79 milj. USD20232024: 6,3 milj. USD2024: EBIT −61 milj. USD20242025: 44 milj. USD2025: EBIT −42 milj. USD202544−42
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Tumor-activated cytokine therapies35 %

Engineered IL-12-based oncology programs designed to activate in tumors.

Masked T cell engagers30 %

Conditionally activated T cell engager molecules for cancer targets.

Masked antibody-based immunotherapies20 %

Antibody therapeutics designed to reduce systemic activity and improve selectivity.

Research and development collaborations15 %

Partnered discovery, development, and option agreements with pharma collaborators.

Asiakkaat

Xilio’s direct counterparties are pharmaceutical partners rather than end patients, since the company monetizes its science through collaborations, licenses, and option agreements. Its programs are aimed at oncology drug developers seeking differentiated immunotherapy assets that can be advanced into clinical development and commercialization. In the longer term, if products are approved, the ultimate end customers would be cancer patients treated through hospitals and oncology centers.

Pharmaceutical collaboration partners

Companies such as Gilead and AbbVie that license or option Xilio programs for development and commercialization.

Clinical trial ecosystem

Hospitals, investigators, and trial networks that support testing of Xilio’s oncology candidates.

Future oncology treatment providers

Hospitals and cancer centers that would use approved therapies if any candidates reach market.

Strategia

Xilio’s strategy is to advance tumor-activated immunotherapy assets while using partnerships to share development risk and extend reach. The company is prioritizing collaboration structures, option deals, and licensing transactions that can fund research while preserving upside in its pipeline. Its long-term position depends on generating clinical proof of concept and converting platform science into partnered or approved oncology products.

Expand and maintain strategic collaborationsLyhyt aikaväli

Partnerships provide funding, validation, and commercialization reach for early-stage assets.

Advance masked immunotherapy pipelineKeskipitkä aikaväli

Clinical and preclinical progress is needed to create value and attract partners or approvals.

Secure capital to fund operationsLyhyt aikaväli

Early-stage biotech development requires external financing before product revenue exists.

Maantiede

Xilio is headquartered in the United States and conducts its corporate and research activities from there. Its business model is global in scope because its collaboration agreements grant worldwide development and commercialization rights to partners, even though the company itself is still centered in U.S.-based operations.

Riskit

Xilio is exposed to the execution risk typical of early-stage biotech companies: its programs may fail in preclinical or clinical development, and partners may not prioritize or continue development. The company also depends on external capital and collaboration economics, so financing availability, dilution, and partner decision-making can materially affect its ability to progress the pipeline.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing and going-concern risk1Clinical development failure2Partner dependence and limited control over partnered programs3Competitive pressure in oncology immunotherapy4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company needs substantial additional capital before product revenue is available.

    KohdistuuEquity issuanceWarrantsCollaborations
  2. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    Early-stage oncology candidates may not show sufficient safety or efficacy.

    Kohdistuu: Preclinical and clinical pipeline

  3. Partner dependence and limited control over partnered programsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Collaborators can decide whether and how quickly to advance licensed assets, affecting timing and value capture.

    KohdistuuGileadAbbVieRoche collaborations
  4. Competitive pressure in oncology immunotherapyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Larger pharma and biotech firms may develop similar or superior therapies faster.

    KohdistuuMasked biologicsT cell engagersCytokine therapies

Kirjanpito

Harkinnanvaraiset erät
Fair value measurement of warrant liabilities

Changes in valuation assumptions can create non-cash gains or losses that affect reported results.

Vaikutus: Common stock warrant liabilities

Collaboration and license accounting

Upfront fees, option payments, and milestones require judgment on performance obligations and timing.

Vaikutus: Revenue and deferred revenue

Research and development expense estimation

Clinical, manufacturing, and external development costs must be accrued based on estimates.

Vaikutus: Operating expenses

Going-concern assessment

Cash runway assumptions influence disclosure and investor interpretation of liquidity risk.

Vaikutus: Liquidity disclosures

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Elicio Therapeutics, Inc.

ELTX · Pharmaceutical Preparations

Phio Pharmaceuticals Corp.

PHIO · Pharmaceutical Preparations

XBiotech Inc.

XBIT · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026